Unknown

Dataset Information

0

Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies.


ABSTRACT: Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may facilitate drug-drug interaction and dose individualization studies with cytotoxic drugs, without causing harm to patients. Therefore, a highly sensitive bioanalytical assay is required. A reversed-phase ultra-high performance liquid chromatography method was developed to determine pemetrexed concentrations in human ethylenediaminetetraacetic acid-plasma after microdosing. [13 C5 ]-Pemetrexed was used as the internal standard. The sample preparation involved solid-phase extraction from plasma. Detection was performed using MS/MS in a total run time of 9.5 min. The assay was validated over the concentration range of 0.0250-25.0 μg/L pemetrexed. The average accuracies for the assay in plasma were 96.5 and 96.5%, and the within-day and between-day precision in coefficients of variations was <8.8%. Extraction recovery was 59 ± 1 and 55 ± 5% for pemetrexed and its internal standard. Processed plasma samples were stable for 2 days in a cooled autosampler at 10°C. The assay was successfully applied in a pharmacokinetic curve, which was obtained as a part of an ongoing clinical microdosing study.

SUBMITTER: van Ewijk-Beneken Kolmer EWJ 

PROVIDER: S-EPMC9285051 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6002064 | biostudies-literature
| S-EPMC3573895 | biostudies-literature
| S-EPMC5145167 | biostudies-literature
| S-EPMC5611668 | biostudies-literature
| S-EPMC7443224 | biostudies-literature
| S-EPMC9369825 | biostudies-literature
| S-EPMC6480583 | biostudies-literature
| S-EPMC5668284 | biostudies-literature
| S-EPMC7065026 | biostudies-literature
| S-EPMC9062210 | biostudies-literature